SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors
Improving Medication Adherence With Adjuvant Aromatase Inhibitor in Women With Breast Cancer: A Randomised Controlled Trial to Evaluate the Effect of Short Message Service (SMS) Reminder
1 other identifier
interventional
244
1 country
2
Brief Summary
The purpose of this study is to determine whether weekly SMS reminders are effective in improving medication adherence of adjuvant aromatase inhibitors in women with breast cancer.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable breast-cancer
Started May 2015
Typical duration for not_applicable breast-cancer
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2015
CompletedFirst Submitted
Initial submission to the registry
August 11, 2015
CompletedFirst Posted
Study publicly available on registry
August 17, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2020
CompletedJune 29, 2020
June 1, 2020
4.6 years
August 11, 2015
June 25, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Medication adherence
Simplified medication adherence questionnaire (SMAQ)
One year
Secondary Outcomes (3)
Androstenedione
One year
Estrone
One year
Estradiol
One year
Other Outcomes (2)
Patients' knowledge, attitude, and behavior towards medication adherence
One year
Patients' knowledge, attitude, and behavior towards medication adherence
One year
Study Arms (2)
SMS reminder
EXPERIMENTALWeekly SMS reminder to take aromatase inhibitors as prescribed by doctor
Standard care
NO INTERVENTIONRoutine care
Interventions
Weekly SMS reminder to take aromatase inhibitors as prescribed by doctor for 1 year
Eligibility Criteria
You may qualify if:
- Women who have been receiving adjuvant endocrine therapy for at least 1 year, and are continuing to receive adjuvant AI therapy for at least 1 more year.
- Have cellular phone that can receive text messages.
- Singaporean or permanent resident who is currently residing in Singapore.
- Able to give informed consent.
You may not qualify if:
- \. Unable or not willing to comply with study procedures.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- National University of Singaporelead
- Singapore Cancer Societycollaborator
Study Sites (2)
National University Hospital
Singapore, 119628, Singapore
Ng Teng Fong General Hospital
Singapore, 609606, Singapore
Related Publications (1)
He Y, Tan EH, Wong ALA, Tan CC, Wong P, Lee SC, Tai BC. Improving medication adherence with adjuvant aromatase inhibitor in women with breast cancer: study protocol of a randomised controlled trial to evaluate the effect of short message service (SMS) reminder. BMC Cancer. 2018 Jul 9;18(1):727. doi: 10.1186/s12885-018-4660-7.
PMID: 29986672DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Bee Choo Tai, PhD
National University of Singapore
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- HEALTH SERVICES RESEARCH
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
August 11, 2015
First Posted
August 17, 2015
Study Start
May 1, 2015
Primary Completion
December 1, 2019
Study Completion
January 1, 2020
Last Updated
June 29, 2020
Record last verified: 2020-06
Data Sharing
- IPD Sharing
- Will not share